Navigation Links
Cancer Research UK's new funding scheme to nurture future world-leading scientists
Date:7/2/2014

A NEW funding scheme will support mid-career scientists looking to take the next steps in their careers, at a point when funding opportunities can be limited.

Cancer Research UK's Programme Foundation Award* will bridge the gap for researchers who have the potential to be the next world-leaders in cancer research but not yet at the level to compete with senior scientists for Cancer Research UK's Programme Awards the largest award Cancer Research UK makes to research groups.

This award is the first of Cancer Research UK's increased investment in research announced as part of its new research strategy.

The Programme Foundation Award will provide funding of up to 1.5 million over six years. The funding will cover staff salaries, PhD students, running costs and equipment. Typically a researcher will have around eight to 14 years post-doctoral experience when applying for the award.

Dr Iain Foulkes, Cancer Research UK's executive director of strategy and research funding, said: "Researchers are vital for what we do we rely on their curiosity, passion and questioning to make the breakthroughs that will help more people survive cancer. But for many years there has been a 'missing link' in funding schemes to take researchers from the early stages in their career to being the leading stars of cancer research. The Programme Foundation Award will bridge this gap."

Cancer Research UK is also changing the eligibility criteria for another of its awards the Career Establishment Award. This will now support researchers for six years, rather than five, meaning that there are funding opportunities for scientists at all stages of their careers with holders of the Career Establishment Awards expected to progress onto the Programme Foundation Award.

Supporting researchers at all stages of their careers has long been at the heart of Cancer Research UK's work with over 35 million spent each year helping to develop the research leaders of tomorrow. This month the charity supported the largest number ever of awards to support researchers taking the next steps in their careers. This includes seven Career Development Fellowships, two Career Establishment Awards, two Senior Cancer Research Fellowships and five Clinician Scientist Fellowships.

The Programme Foundation Award forms part of Cancer Research UK's ambitious new research strategy. The charity will invest up to 50 million a year in a range of new funding schemes covering some of the biggest questions in cancer research. These will range from schemes to develop the next generation of researchers to those addressing specific research questions to improve our understanding of the disease and find better and kinder treatments.

Professor Nic Jones, Cancer Research UK's chief scientist, said: "The new Programme Foundation Award positions the UK as one of the best places in the world for a scientist to develop their career in cancer research. We want to recruit the best people and help them grow at every step of their career. The medical breakthroughs of tomorrow start with investment in today's cancer researchers. This is how we will get to our aim of getting three-quarters of people surviving cancer in the next 20 years."


'/>"/>

Contact: Simon Shears
simon.shears@cancer.org.uk
44-203-469-8054
Cancer Research UK
Source:Eurekalert

Related medicine news :

1. Biomarker predicts effectiveness of brain cancer treatment
2. GW researcher receives more than $1 million in grants to study epigenetics of pancreatic cancer
3. For cancer patients, sugar-coated cells are deadly
4. Mayo Clinic: Proton therapy has advantages over IMRT for advanced head and neck cancers
5. Mayo Clinic researchers reveal treasure trove of genes key to kidney cancer
6. Enlightening cancer cells
7. Cancer risk: Aspirin and smoking affect aging of genes
8. EORTC presents European solution for effective cancer drug development
9. New approach identifies cancer mutations as targets of effective melanoma immunotherapy
10. Case Western Reserve, University Hospitals fundraising for adolescent, young adult cancer
11. Improved survival with TAS-102 in mets colorectal cancer refractory to standard therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 29, 2017 , ... The ... Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, ... questions regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... services, is proud to announce it has joined the National Association for Home ... interests of chronically ill, disabled, and dying Americans of all ages and the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, ... and efficacy studies. The company is harnessing the power ... MAGE A, in an effort to find a better ... After 4 weeks of treatment in transgenic mice, the ... in a full toxicology report of various organs. Cytotoxic ...
Breaking Medicine Technology: